Differential Long-Term Effects of First- and Second-Generation DES in Patients With Bifurcation Lesions Undergoing PCI

[1]  S. Pocock,et al.  Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. , 2020, Journal of the American College of Cardiology.

[2]  M. Jeong,et al.  Prognostic Effects of Treatment Strategies for Left Main Versus Non-Left Main Bifurcation Percutaneous Coronary Intervention With Current-Generation Drug-Eluting Stent , 2020, Circulation. Cardiovascular interventions.

[3]  T. Akasaka,et al.  7-Year Outcomes of a Randomized Trial Comparing the First-Generation Sirolimus-Eluting Stent Versus the New-Generation Everolimus-Eluting Stent: The RESET Trial. , 2019, JACC. Cardiovascular interventions.

[4]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[5]  R. Kornowski,et al.  Temporal trends in percutaneous coronary interventions thru the drug eluting stent era: Insights from 18,641 procedures performed over 12‐year period , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  J. Spertus,et al.  Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, Circulation.

[7]  J. Spertus,et al.  Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, European heart journal.

[8]  K. Bønaa,et al.  Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. , 2016, The New England journal of medicine.

[9]  A. Kaltoft,et al.  Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV. , 2016, Journal of the American College of Cardiology.

[10]  Yong Hwan Park,et al.  Long-Term Clinical Outcomes of True and Non-True Bifurcation Lesions According to Medina Classification- Results From the COBIS (COronary BIfurcation Stent) II Registry. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[11]  M. Jeong,et al.  Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. , 2015, JACC. Cardiovascular interventions.

[12]  M. Jeong,et al.  Comparison of the first- and second-generation limus-eluting stents for bifurcation lesions from a Korean multicenter registry. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[13]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  M. Jeong,et al.  Differential prognostic impact of treatment strategy among patients with left main versus non-left main bifurcation lesions undergoing percutaneous coronary intervention: results from the COBIS (Coronary Bifurcation Stenting) Registry II. , 2014, JACC. Cardiovascular interventions.

[15]  M. Niemelä,et al.  Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. , 2013, Journal of the American College of Cardiology.

[16]  Per Albertsson,et al.  Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). , 2013, Journal of the American College of Cardiology.

[17]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[18]  F. Eberli,et al.  Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.

[19]  A. M. Leone,et al.  Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. , 2011, JACC. Cardiovascular interventions.

[20]  Jun-Jie Zhang,et al.  A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. , 2011, Journal of the American College of Cardiology.

[21]  F. Eberli,et al.  Drug-eluting versus bare-metal stents in large coronary arteries. , 2010, The New England journal of medicine.

[22]  A. Baumbach,et al.  Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies , 2010, Circulation.

[23]  E. Bramucci,et al.  Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study , 2009, Circulation.

[24]  F. Neumann,et al.  Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions , 2008, European heart journal.

[25]  Antonio Colombo,et al.  Bifurcation disease: what do we know, what should we do? , 2008, JACC. Cardiovascular interventions.

[26]  Ron Goeree,et al.  Effectiveness and safety of drug-eluting stents in Ontario. , 2007, The New England journal of medicine.

[27]  M. Niemelä,et al.  Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Study , 2006, Circulation.

[28]  Alfonso Medina,et al.  Una clasificación simple de las lesiones coronarias en bifurcación , 2006 .

[29]  J. Suárez de Lezo,et al.  [A new classification of coronary bifurcation lesions]. , 2006, Revista espanola de cardiologia.

[30]  Patrick W Serruys,et al.  Late angiographic stent thrombosis (LAST) events with drug-eluting stents. , 2005, Journal of the American College of Cardiology.

[31]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[32]  Lawrence Joseph,et al.  A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents , 2004, The Lancet.

[33]  S. Bangalore.  Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease , 2016, The New England journal of medicine.

[34]  P. Kolh,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca , 2014, European heart journal.

[35]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[36]  G. Levine,et al.  ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions , 2011 .

[37]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .